The main HER2 scoring systems that are being used include guidelines for HER2 testing in breast cancer and in gastric/gastroesophageal (GE) cancer (both ASCO/CAP in the US and ESMO guidelines in Europe) and the HER2 scoring system developed for CRC in the HERACLES clinical trial (Table 1). This evidence concerns the gene ERBB2 and breast cancer.